Vanderbilt-Ingram Cancer Center

Vanderbilt-Ingram website >

The Vanderbilt team studying histoplasmosis includes (front row, from left, Heidi Chen, PhD, Melinda Aldrich, PhD, MPH, (back row, from left) Stephen Deppen, PhD, Eric Grogan, MD, MPH, and Jeffrey Blume, PhD.
April 18, 2019

Team explores fungal infection quandary in lung cancer screenings

Serving a region that lies within the tobacco belt, clinicians at Vanderbilt Health face challenges distinguishing lung cancer from histoplasmosis, a fungal infection that creates cancer-mimicking lesions in the lungs.

By Tom Wilemon
From left, Benjamin Brown, Christine Lovly, MD, PhD, Yun-Kai Zhang, PhD, Jens Meiler, PhD, and colleagues are exploring new ways to understand resistance to targeted cancer therapy drugs.
April 11, 2019

Study reframes approach to targeted therapy resistance

When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.

By Tom Wilemon
Longtime colleagues and friends Curt Thorne, left, and Terry Burke enjoyed sailing together.
March 28, 2019

Bladder cancer research fund honors mentor’s lasting influence

The Terry Burke Fund for Bladder Cancer Research at Vanderbilt-Ingram Cancer Center is supporting a range of discovery research aimed at improving outcomes for bladder cancer patients, and it is helping train the next generation of bladder cancer physician-scientists.

By Leigh MacMillan
March 14, 2019

Cancer Center Ambassadors surpass $1 million in grants

Vanderbilt-Ingram Cancer Center Ambassadors surpassed the $1 million mark with the awarding of the group’s latest research grants.

By Tom Wilemon
February 28, 2019

Investigators map genomic landscape of very rare cancer

A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.

By Tom Wilemon
February 28, 2019

VICC launches new telehealth program for CAR-T patients

Some cancer patients receiving CAR-T infusions can now avoid hospital stays because of a telemedicine program launched by Vanderbilt-Ingram Cancer Center.

By Tom Wilemon
January 31, 2019

Grant supports novel imaging initiative to enhance cancer care

A Vanderbilt initiative to develop predictive imaging technologies that clinicians can use to better match patients with personalized care has received National Cancer Institute (NCI) funding.
By Tom Wilemon
October 4, 2018

VICC’s Levy to lead Rush University Cancer Center

Mia Levy, MD, PhD, director of Cancer Health Informatics and Strategy at Vanderbilt-Ingram Cancer Center (VICC) and Ingram Associate Professor of Cancer Research, has been named director of Rush University Cancer Center and Systems Vice President for Cancer Service at Rush University Medical Center in Chicago.
By Tom Wilemon
May 17, 2018

Park named to VICC breast cancer leadership position

By Doug Campbell
January 18, 2018

Study finds higher death rates in poor neighborhoods

Living in an economically disadvantaged neighborhood is likely to lead to death at an earlier age, especially among African-Americans, new research shows. The death rate is even more pronounced among disadvantaged individuals with unhealthy lifestyle habits.
By VUMC News and Communications
November 9, 2017

Mathis strives to make her cancer journey meaningful

Amanda Mathis, chief financial officer of Bridgestone Americas, was just 35 when she first felt a lump in her right breast.
By VUMC News and Communications
October 25, 2017

Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR-T therapy

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR-T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.
By VUMC News and Communications
August 3, 2017

Investigators match novel cancer mutations with potential therapies

Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients.
By VUMC News and Communications